Alspaugh Jonathan
Known title: Chief Financial OfficerCIK: 0001868112
Alspaugh Jonathan's purchase track record
How the stock did after each of Alspaugh Jonathan's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since August 16, 2021
Stock higher 6 months later
0%
3 months: 33%
Median 6-month return
-75.4%
3 months: -41.4%
Beat the S&P 500
0%
median -66.0% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/11/2022 | SYRE | $156K | -64.3% | -75.4% | -3.3% |
| 12/9/2021 | SYRE | $186K | -41.4% | -79.9% | -13.9% |
| 8/16/2021 | SYRE | $263K | +11.7% | -47.7% | -1.7% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| SYRE | ▲ Buy | Open Market | 75,000 | $156K | 3/11/2022 | View on chart |
| SYRE | ▲ Buy | Open Market | 50,000 | $186K | 12/9/2021 | View on chart |
| SYRE | ▲ Buy | Open Market | 7,200 | $48K | 8/18/2021 | View on chart |
| SYRE | ▲ Buy | Open Market | 23,392 | $152K | 8/17/2021 | View on chart |
| SYRE | ▲ Buy | Open Market | 9,780 | $62K | 8/16/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Spyre Therapeutics Launches $350M Public Offering, Stock Drops
Spyre Therapeutics has priced a $350 million public offering of common stock, which led to a decline in the share price on the launch day. The company also announced inducement awards to support its growth. Analysts from JP Morgan and BTIG have begun coverage, citing a target price around $110 to $121. The offering and analyst interest may influence the stock’s short‑term trajectory.
Spyre Therapeutics Launches $350M Public Offering, Stock Drops. Spyre Therapeutics has priced a $350 million public offering of common stock, which led to a decline in the share price on the launch day. The company also announced inducement awards to support its growth. Analysts from JP Morgan and BTIG have begun coverage, citing a target price around $110 to $121. The offering and analyst interest may influence the stock’s short‑term trajectory.